Small Biotech Promosome Drops Lawsuit Against Pfizer, BioNTech in COVID-19 Vaccine Patent Dispute
Portfolio Pulse from Vandana Singh
Biotech firm Promosome has dropped its lawsuit against Pfizer Inc and BioNTech SE over alleged patent infringement related to mRNA technology used in their COVID-19 vaccines. The financial terms of the agreement were not disclosed. Promosome had previously dropped a similar lawsuit against Moderna Inc. However, the legal battle between Moderna and Pfizer/BioNTech over patents remains ongoing.
October 05, 2023 | 7:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech's legal dispute with Promosome over alleged patent infringement has been resolved. The financial terms of the agreement were not disclosed.
The resolution of the lawsuit removes a potential legal risk for BioNTech. However, the undisclosed financial terms of the agreement could have an impact on BioNTech's financials.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Pfizer's legal dispute with Promosome over alleged patent infringement has been resolved. The financial terms of the agreement were not disclosed.
The resolution of the lawsuit removes a potential legal risk for Pfizer. However, the undisclosed financial terms of the agreement could have an impact on Pfizer's financials.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
NEUTRAL IMPACT
Arbutus Biopharma Corporation and its licensee Genevant Sciences have an ongoing lawsuit against Pfizer and BioNTech for alleged patent infringement.
The ongoing lawsuit against Pfizer and BioNTech could potentially impact Arbutus Biopharma Corporation's financials and reputation, depending on the outcome.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50
NEUTRAL IMPACT
Moderna's legal dispute with Promosome over alleged patent infringement has been resolved. However, the legal battle between Moderna and Pfizer/BioNTech over patents remains ongoing.
While the resolution of the lawsuit with Promosome removes a potential legal risk for Moderna, the ongoing legal battle with Pfizer/BioNTech over patents could still pose a risk.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100